

SHORT META-ANALYSIS · Peer-reviewed · Published · Computed forest plot

Sotagliflozin SGLT1/2i: A Transparent Living Meta-Analysis v13

Sara Ahmed Ahmed & Mahmood Ahmad

¹ Royal Free London NHS Foundation Trust, London, UK² Tahir Heart Institute, Rabwah, Pakistan

Correspondence: Dr Mahmood Ahmad <mahmood726@gmail.com> · ORCID 0000-0001-9107-3704

Article 104 · Volume 2 · Published 2026-06-06 · DOI: not assigned

KEY WORDS Heart Failure; SGLT2 Inhibitors; meta-analysis; randomised trials

Abstract

Patients with type 2 diabetes or recent worsening heart failure remain at high cardiovascular risk; does the use of Sotagliflozin across both settings help to reduce this? This living meta-analysis included 11,806 participants from the randomized placebo-controlled SCORED and SOLOIST-WHF trials. Hazard ratios were combined using inverse-variance fixed-effect modelling on the logarithmic scale. The pooled estimate for the primary cardiovascular composite outcome was 0.72 (95% CI 0.63–0.82) without observed heterogeneity ($I^2 = 0\%$). Both trials individually supported Sotagliflozin, with SCORED reporting a hazard ratio of 0.74 and SOLOIST-WHF reporting 0.67. These findings suggest that Sotagliflozin lowers cardiovascular event risk by nearly twenty-eight percent in chronic diabetes and recently decompensated heart failure populations. Interpretation should consider possible variation during post-discharge treatment periods, the early termination of SOLOIST-WHF as well as the need for continued surveillance of ketoacidosis ri

Forest plot and risk of bias

This is a comparative meta-analysis of two randomised, placebo-controlled trials of sotagliflozin (SCORED and SOLOIST-WHF; 11,806 participants). The figures below are rendered directly from the living dashboard's per-trial data: each trial's published hazard ratio is plotted, and the pooled diamond is an independent inverse-variance recompute that reproduces the dashboard's headline estimate (HR 0.72, 95% CI 0.63–0.82, $I^2 = 0\%$; analysed arms sum to 11,806). **Living dashboard:** <https://mahmood726-cyber.github.io/Sotagliflozin-LivingMeta/>




Figure 1. Forest plot of the primary cardiovascular composite outcome. Per-trial hazard ratios (95% CI) are the published SCORED (0.74, 0.63–0.88) and SOLOIST-WHF (0.67, 0.52–0.85) values entered in the living dashboard; the pooled diamond is an inverse-variance synthesis on the log-hazard scale (REML). With $I^2 = 0\%$ this coincides with the fixed-effect estimate reported in the abstract: HR 0.72 (95% CI 0.63–0.82).




Figure 2. Risk-of-bias summary (RoB 2 domains). Domain-level risk-of-bias judgements for each included randomised trial.

HOW TO CITE

Sara Ahmed Ahmed & Mahmood Ahmad. Sotagliflozin SGLT1/2i: A Transparent Living Meta-Analysis v13. *Synthesis* 2026;8(1). Article 104. Available at <https://synthesis-medicine.org/index.php/journal/article/view/104>. Licensed under CC BY 4.0. DOI: not assigned.

Reproducibility & data provenance. The forest plot is computed from the two trials' published hazard ratios as entered in the living dashboard (SCORED: Bhatt DL et al., *N Engl J Med* 2021; SOLOIST-WHF: Bhatt DL et al., *N Engl J Med* 2021). The pooled estimate is an independent inverse-variance synthesis on the log-hazard scale that reproduces the dashboard's published value (HR 0.72, 95% CI 0.63–0.82, $I^2 = 0\%$); with no heterogeneity it coincides with the fixed-effect estimate stated in the abstract. The article text, authors, abstract, issue and licence follow the journal's published record.

Copyright (c) 2026 Sara Ahmed Ahmed, Mahmood Ahmad. Open access under the Creative Commons Attribution 4.0 International licence (CC BY 4.0): free to share and adapt with attribution.

Published in *Synthesis*

· synthesis-medicine.org